Gufic Biosciences Limited (GUFICBIO.NS)
INR 316.35
(2.03%)
INR 316.35
(2.03%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.32 Billion INR | -0.38% |
| 2022 | 3.34 Billion INR | 419.03% |
| 2021 | 643.87 Million INR | 4.63% |
| 2020 | 615.37 Million INR | -48.87% |
| 2019 | 1.2 Billion INR | 23.09% |
| 2018 | 977.85 Million INR | 22.77% |
| 2017 | 796.48 Million INR | 40.21% |
| 2016 | 568.06 Million INR | 32.86% |
| 2015 | 427.57 Million INR | 30.28% |
| 2014 | 328.18 Million INR | -1.75% |
| 2013 | 334.03 Million INR | -4.09% |
| 2012 | 348.29 Million INR | 77.36% |
| 2011 | 196.37 Million INR | -5.87% |
| 2010 | 208.63 Million INR | 19.13% |
| 2009 | 175.12 Million INR | 15.68% |
| 2008 | 151.38 Million INR | -7.39% |
| 2007 | 163.46 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 3.58 Billion INR | 0.0% |
| 2023 FY | 3.32 Billion INR | -0.38% |
| 2023 Q4 | 3.32 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q4 | 3.34 Billion INR | 0.0% |
| 2022 FY | 3.34 Billion INR | 419.03% |
| 2022 Q2 | 1.85 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 643.87 Million INR | 4.63% |
| 2021 Q2 | 353.16 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 643.87 Million INR | 0.0% |
| 2020 Q2 | 1.27 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 615.37 Million INR | -48.87% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 615.37 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 1.2 Billion INR | 23.09% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 1.13 Billion INR | 0.0% |
| 2019 Q4 | 1.2 Billion INR | 0.0% |
| 2018 Q4 | 977.85 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 908.71 Million INR | 0.0% |
| 2018 FY | 977.85 Million INR | 22.77% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 796.48 Million INR | 40.21% |
| 2017 Q4 | 796.48 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 744.55 Million INR | 0.0% |
| 2016 Q2 | 420.87 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 568.06 Million INR | 32.86% |
| 2016 Q4 | 568.06 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 427.57 Million INR | 30.28% |
| 2015 Q4 | 427.57 Million INR | 0.0% |
| 2015 Q2 | 352.66 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 275.66 Million INR | 0.0% |
| 2014 FY | 328.18 Million INR | -1.75% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 328.18 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 326.34 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 334.03 Million INR | 0.0% |
| 2013 FY | 334.03 Million INR | -4.09% |
| 2012 FY | 348.29 Million INR | 77.36% |
| 2012 Q4 | 348.29 Million INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q2 | - INR | 0.0% |
| 2011 FY | 196.37 Million INR | -5.87% |
| 2011 Q4 | 196.37 Million INR | 0.0% |
| 2010 FY | 208.63 Million INR | 19.13% |
| 2009 FY | 175.12 Million INR | 15.68% |
| 2008 FY | 151.38 Million INR | -7.39% |
| 2007 FY | 163.46 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Aarti Drugs Limited | 5.64 Billion INR | 41.001% |
| Albert David Limited | 33.24 Million INR | -9914.912% |
| Alembic Limited | 91.5 Million INR | -3538.423% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -75752.29% |
| Hester Biosciences Limited | 2.44 Billion INR | -36.23% |
| Hikal Limited | 8.17 Billion INR | 59.28% |
| Ind-Swift Limited | 10.13 Billion INR | 67.168% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -951.983% |
| Unichem Laboratories Limited | 2.47 Billion INR | -34.504% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 35.124% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -1265.007% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -0.027% |
| Brooks Laboratories Limited | 56.41 Million INR | -5800.773% |
| Eris Lifesciences Limited | 27.81 Billion INR | 88.03% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 67.087% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -3623.473% |
| Wanbury Limited | 1.16 Billion INR | -185.802% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -16.71% |
| Alkem Laboratories Limited | 14.18 Billion INR | 76.529% |
| FDC Limited | 205.18 Million INR | -1522.515% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -1841.426% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -1902.91% |
| Innova Captab Limited | 2.45 Billion INR | -35.826% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -916.226% |
| Ipca Laboratories Limited | 14.38 Billion INR | 76.854% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 90.914% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -31106.946% |
| Lupin Limited | 29.21 Billion INR | 88.606% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -238.011% |
| Medico Remedies Limited | 80.5 Million INR | -4035.393% |
| Morepen Laboratories Limited | 289.99 Million INR | -1048.017% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 47.617% |
| Orchid Pharma Limited | 1.35 Billion INR | -146.275% |
| Procter & Gamble Health Limited | 95.6 Million INR | -3382.382% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Sigachi Industries Limited | 1.43 Billion INR | -132.724% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 89.831% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -412.206% |
| Themis Medicare Limited | 957.92 Million INR | -247.539% |
| Vaishali Pharma Limited | 134.91 Million INR | -2367.541% |
| Venus Remedies Limited | 413.3 Million INR | -705.506% |
| Windlas Biotech Limited | 36.41 Million INR | -9043.524% |
| ZIM Laboratories Limited | 1.08 Billion INR | -205.92% |
| Sakar Healthcare Limited | 793.51 Million INR | -319.545% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 94.992% |
| Divi's Laboratories Limited | 30 Million INR | -10997.19% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -7140.131% |
| Mankind Pharma Limited | 2.07 Billion INR | -60.695% |
| Sequent Scientific Limited | 4.87 Billion INR | 31.737% |
| Laurus Labs Limited | 25.77 Billion INR | 87.083% |
| Neuland Laboratories Limited | 953.89 Million INR | -249.006% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 11.848% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 72.954% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 58.603% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -19162.611% |
| Wockhardt Limited | 23.56 Billion INR | 85.869% |
| Bal Pharma Limited | 1.39 Billion INR | -138.396% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 83.371% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -233.449% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -16799.274% |
| Shilpa Medicare Limited | 9.37 Billion INR | 64.485% |
| Valiant Laboratories Limited | 767.08 Million INR | -334.002% |
| Ajanta Pharma Limited | 352.8 Million INR | -843.639% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | -961.854% |
| Granules India Limited | 13.15 Billion INR | 74.684% |
| Medicamen Biotech Limited | 308.17 Million INR | -980.292% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -359.279% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.379% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 91.723% |
| NATCO Pharma Limited | 3.71 Billion INR | 10.314% |
| Suven Life Sciences Limited | 7.09 Million INR | -46809.356% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -72.112% |
| Strides Pharma Science Limited | 25.16 Billion INR | 86.773% |
| Indoco Remedies Limited | 6.71 Billion INR | 50.456% |
| Alpa Laboratories Limited | 52.46 Million INR | -6245.482% |
| Lasa Supergenerics Limited | 220.76 Million INR | -1408.03% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -444.425% |